Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Iron Mountain Inc (IRM) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

Iron Mountain (IRM) trades at $121.50, up 1.69% today, with strong recent earnings beats and a bullish analyst consensus of 65% buy ratings. The stock shows a bearish technical signal but is supported by positive momentum in data center demand and a recent $1.5 billion debt offering. Revenue growth is steady, though net margins are thin at 3.76%, and the company carries high debt levels with a debt-to-asset ratio of 74.39% as of 2024.

Outlook is mixed: robust data center growth and dividend yield offer upside, but high valuation (P/E 132.08) and leverage pose risks. The consensus price target of $138.67 suggests 14% potential upside, yet technical resistance near $122 may limit near-term gains. Investors should weigh strong institutional support against elevated financial risk.